End-of-day quote
Other stock markets
|
||
- USD | - |
05-21 | Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise | MT |
05-17 | Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study | CI |
Sales 2024 * | 374K 509K | Sales 2025 * | 488K 664K | Capitalization | 40.2M 54.79M |
---|---|---|---|---|---|
Net income 2024 * | -5M -6.81M | Net income 2025 * | -7M -9.54M | EV / Sales 2024 * | 108 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 82.5 x |
P/E ratio 2024 * |
-6.93
x | P/E ratio 2025 * |
-6.86
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.23% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
John Docherty
PSD | President | 53 | 15-04-14 |
George Jurcic
IRC | Investor Relations Contact | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 11-07-07 |
Albert Reese
BRD | Director/Board Member | 74 | 21-01-13 |
1st Jan change | Capi. | |
---|---|---|
+38.51% | 727B | |
+31.74% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |